Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of anlotinib in advanced medullary thyroid carcinoma
CTR20244102Phase 4Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anlotinib in Medullary Thyroid Cancer (MTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2023; status: active.
02
Drugs
anlotinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on CTR20244102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244102.